Zetagen Therapeutics Inc.
Founded in 2015, Zetagen is a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions. Our multi-patented, ZetaMet technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. Zetagen exclusively-licensed the platform technology from the State University of New York in 2016. Our goal is to help the hundreds of thousands of people diagnosed with metastatic bone cancers and millions of people needing osteologic intervention. This novel therapy, a drug-eluting implant technology, has successfully passed its preclinical trials and is being prepared for its first human clinical trial in early 2022. In addition to ZetaMet, the Company’s pipeline includes other oncologic treatments for Skeletal Related Events (SREs), i.e., ZetaMet Settable™ and ancillary osteologic treatments including, ZetaFuse, ZetaSet, ZetaDent and ZetaBase.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Nationally (across the country)
- Year Founded:
- 2015
The Science
Zetagen discovered and patented a new molecular pathway via a safe and proven small molecule which was originally approved by the FDA in 1971 to produce a truly inductive biologic to inhibit bone metastases and regenerate bone. Through this new mechanism of action (MOA), which is a novel molecular pathway, this small molecule, precisely-dosed, delivered to the affected area through a proprietary drug-eluting carrier, stimulates stem cells, activating cells to grow healthy bone known as “osteoblasts”, and inhibits cells associated with bone degradation called “osteoclasts”.
Our product, ZetaMet™ has thus far demonstrated its ability to resolve existing metastatic bone lesions, inhibit pain, and stimulate targeted bone regeneration.
Zetagen has performed invitro human mesenchymal stem cells (hMSC), controlled and GLP preclinical studies substantiating these claims. These data have been submitted to Health Canada and the FDA.
Research
Our Mission is to develop the broadest range of clinical therapies with our breakthrough technology to benefit as many patients as possible suffering from metastatic bone cancer.
“Research never ceases at Zetagen because cancer never rests…”
We are appreciative to have the financial support of our investors and the National Institute of Health (NIH) through their variety of Small Business Innovation Research (SIBR) programs to support our research. Zetagen’s preclinical research is funded through a series of phase I and II grants from the National Cancer Institute (NCI) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the NIH.
ZetaMet™ was recently awarded a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic bone cancer. Currently, ZetaMet™ is being reviewed by the FDA and Health Canada for a human clinical study for patients living with metastatic breast cancer. Enrollment for this study is scheduled for Q2-2022. Zetagen has several therapies in various stages of development.